CSF Tau Biomarkers Associate With Cognitive Impairment in ALS

The Expanding Spectrum of Cognitive Dysfunction in Motor Neuron Disease

Amyotrophic lateral sclerosis is increasingly recognized as a multisystem neurodegenerative disorder where extra-motor manifestations, particularly cognitive and behavioral changes, occur in up to 50% of patients [1]. These non-motor symptoms are associated with a poorer prognosis and increased caregiver burden, yet they remain inconsistently evaluated in clinical settings and therapeutic trials [2, 3]. While the C9orf72 repeat expansion and bulbar-onset disease are established risk factors for cognitive decline, the underlying molecular drivers of these deficits often remain obscure [4]. Beyond the classic motor neuron involvement, the disease spectrum may also include sensory neuropathies and complex neuropsychiatric profiles that complicate the clinical trajectory [5]. To better understand these mechanisms, a new study investigates how co-occurring proteinopathies typically associated with Alzheimer's disease might influence the cognitive status of patients with this motor neuron disease, offering potential new avenues for stratifying patients in clinical practice.

Biomarker Profiling in the ALS-FTD Continuum

To investigate whether pathological changes typically associated with Alzheimer's disease contribute to cognitive impairment in amyotrophic lateral sclerosis, researchers conducted a comprehensive biomarker analysis of 192 individuals diagnosed with ALS or ALS with frontotemporal dementia (ALS-FTD). This clinical cohort was compared against 100 healthy controls to identify specific proteopathic signatures linked to neurodegeneration. The researchers utilized the Edinburgh Cognitive and Behavioral ALS Screen (ECAS), a multi-domain assessment specifically designed to evaluate executive functions, social cognition, and language in patients with motor impairment, to categorize the participants' cognitive status. By employing group comparisons and regression analyses, the study examined the precise associations between various biomarker profiles and the degree of cognitive dysfunction across the ALS-FTD spectrum. The methodology involved a dual-fluid approach to capture the complex proteopathic landscape of the disease. The researchers analyzed cerebrospinal fluid (CSF) for total-tau, phosphorylated-tau (p-tau), and beta-amyloid, which serve as established indicators of microtubule stability and amyloid plaque pathology. Simultaneously, the team measured plasma biomarkers, specifically neurofilament light chain (NfL) to assess the rate of large-caliber axonal injury, and extracellular vesicle TDP-43 (a measure of the hallmark ALS protein packaged within small, membrane-bound sacs released into the bloodstream). This multifaceted profiling allowed the investigators to determine if the cognitive deficits observed in ALS are driven primarily by the classic TDP-43 pathway or if co-occurring Alzheimer's-related proteinopathies play a significant role in the clinical phenotype, a distinction that could eventually guide targeted therapies.

Cerebrospinal Fluid Tau and Amyloid as Cognitive Indicators

The study identified a clear biochemical divergence between patients based on their cognitive status, finding that patients with ALS, particularly those with cognitive impairment (ALSci) or ALS-FTD, showed elevated Alzheimer's-related biomarkers compared with healthy controls. This elevation suggests that the proteopathic landscape of ALS frequently overlaps with pathways typically associated with Alzheimer's disease. Specifically, the researchers observed that significant differences in beta-amyloid levels were present between healthy controls and patients with ALSci, whereas no significant difference in beta-amyloid levels was found between healthy controls and cognitively unimpaired patients. For clinicians, this distinction indicates that amyloid pathology may be specifically linked to the transition from purely motor symptoms to the cognitive deficits observed in the ALSci subgroup. Beyond amyloid, the researchers found that microtubule-associated proteins were highly sensitive indicators of cognitive health. Cerebrospinal fluid phosphorylated-tau (p-tau) and total-tau levels were strongly associated with domain-specific cognitive performance, reflecting a direct link between these markers of axonal damage and the functional deficits measured by the Edinburgh Cognitive and Behavioral ALS Screen. These tau-related CSF biomarkers, particularly p-tau and total-tau, are associated with cognitive deficits in ALS, providing a potential biological explanation for the clinical heterogeneity seen in the disease. However, the diagnostic utility of these markers varied by disease stage. The researchers noted that in vivo biomarkers alone reliably distinguished cognitive impairment only in ALSci and ALS-FTD, suggesting they are most effective as confirmatory indicators once cognitive decline has already manifested clinically rather than as early predictive screening tools.

Divergent Roles of TDP-43 and Neurofilament Light Chain

While cerebrospinal fluid tau species demonstrated a robust correlation with cognitive decline, other systemic biomarkers commonly used in the study of neurodegeneration did not show the same utility for assessing mental status. In the cohort of 192 individuals with amyotrophic lateral sclerosis or amyotrophic lateral sclerosis with frontotemporal dementia, the researchers evaluated the relationship between cognitive performance on the Edinburgh Cognitive and Behavioral ALS Screen and blood-based markers. Specifically, the study found that plasma extracellular vesicle TDP-43 showed weak or no association with cognition, suggesting that the concentration of this protein within circulating blood vesicles may not reflect the specific cortical pathology driving cognitive impairment in these patients. Similarly, the researchers examined neurofilament light chain (NfL), a structural protein released into the blood and cerebrospinal fluid following axonal injury. Although NfL is widely recognized as a sensitive indicator of motor neuron degeneration and overall disease progression, its role as a cognitive marker appears limited in this context. The analysis revealed that plasma neurofilament light chain (NfL) showed weak or no association with cognition among the study participants. This finding is clinically significant for physicians, as it suggests that while elevated NfL levels may confirm active neurodegeneration, they do not necessarily provide insight into a patient's cognitive or behavioral status. These results highlight a divergence between markers of general neuronal damage and markers of cognitive dysfunction. While the postmortem data in this study eventually confirmed that TDP-43 burden in the temporal and hippocampal regions was associated with cognitive dysfunction, the in vivo plasma measurements of extracellular vesicle TDP-43 failed to capture this relationship. For the practicing clinician, this underscores that current plasma-based assays for TDP-43 and NfL, while useful for other diagnostic or prognostic purposes, lack the sensitivity required to monitor the cognitive aspects of the amyotrophic lateral sclerosis spectrum.

Postmortem Insights into Regional Protein Burden

To validate the clinical utility of cerebrospinal fluid biomarkers, the researchers conducted postmortem analyses on a subset of participants to examine the underlying neuropathology. This investigation confirmed that amyotrophic lateral sclerosis and Alzheimer's disease share several neuropathological features, including the accumulation of tau, amyloid, and TDP-43 pathology. Despite these shared characteristics, the standardized measure of Alzheimer's disease neuropathologic change, known as the ABC score (a scale that incorporates amyloid plaque staging, tau neurofibrillary tangle distribution, and neuritic plaque density), did not correlate with the patients' clinical status. Specifically, the researchers found that postmortem analyses showed no strong association between ABC scores and cognitive state, suggesting that while Alzheimer's-related proteins are present in the brains of patients with amyotrophic lateral sclerosis, their global density may not be the primary driver of cognitive decline in this population. The relationship between TDP-43 and cognitive dysfunction proved to be highly dependent on neuroanatomical location rather than total protein volume. While TDP-43 is the hallmark protein of amyotrophic lateral sclerosis, the study found that postmortem analyses showed no strong association between overall TDP-43 burden and cognitive state. Instead, the cognitive deficits observed during life were linked to protein accumulation in specific regions of the brain. The researchers determined that temporal and hippocampal TDP-43 burden was associated with cognitive dysfunction, highlighting the importance of regional pathology in the structures responsible for memory and language processing. Ultimately, the postmortem data showed a stronger relation of TDP-43 pathology to cognitive deficits in amyotrophic lateral sclerosis compared to Alzheimer's-related pathology. For clinicians, this reinforces that while Alzheimer's-associated tau biomarkers serve as useful in vivo indicators of cognitive decline, the localized deposition of TDP-43 remains the true underlying pathological driver of cognitive impairment in the amyotrophic lateral sclerosis spectrum.

References

1. Beswick E, Park E, Wong C, et al. A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis.. Journal of neurology. 2021. doi:10.1007/s00415-020-10203-z

2. Beswick E, Forbes D, Hassan Z, et al. A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis.. Journal of neurology. 2022. doi:10.1007/s00415-021-10651-1

3. Oh J, Oh S. Subjective sleep quality in amyotrophic lateral sclerosis: a systematic review and meta-analysis.. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2026. doi:10.1080/21678421.2026.2614597

4. Yang T, Hou Y, Li C, et al. Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis.. Journal of neurology, neurosurgery, and psychiatry. 2021. doi:10.1136/jnnp-2020-325701

5. Bombaci A, Lupica A, Pozzi FE, Remoli G, Manera U, Stefano VD. Sensory neuropathy in amyotrophic lateral sclerosis: a systematic review.. Journal of neurology. 2023. doi:10.1007/s00415-023-11954-1